FDA Cleared the Omnipod® 5 Automated Insulin Delivery System for Use in People with Type 2 Diabetes
On August 26, 2024, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) had been indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.
“The announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes,”...